Speed Is a Strategy: How Cell and Gene Therapy Developers Can Get to Value Faster

There’s a common assumption in cell and gene therapy that getting the right systems means accepting that implementation takes time. Years, sometimes. Long transformation programs, phased rollouts, heavy configuration work before you ever see the system running on a live therapy. 

We understand why that assumption exists. The complexity of CGT is real. Multiple partners, layered regulatory requirements, intricate supply chains, and the ever-present pressure on HCPs all demand that any orchestration platform can handle serious operational weight. Getting it wrong isn’t just costly; it’s a setback that ripples through to patients. 

But “serious” doesn’t have to mean compromising on speed. And at TrakCel, we think the industry deserves both. 

What therapy developers actually need 

When we talk to therapy developers at all stages, from early clinical programs through to commercial launch preparation, the ask is consistent: speed, certainty, and flexibility. Not one at the expense of another, but all three together. 

Speed, because timelines in CGT aren’t just operational metrics. They affect trial continuity, patient access, cost exposure, and commercial risk. Every month spent waiting for a platform to go live is a month that matters in ways that a standard enterprise software deployment simply doesn’t carry. 

Certainty, because teams need to know what they’re getting into and when they’ll see results. An 18-month implementation roadmap with a value realization point somewhere beyond month twelve isn’t a plan; it’s a risk. 

Flexibility, because no two CGT programs look the same. A company moving a single autologous therapy toward first commercial launch has different needs from a multi-therapy organization managing clinical and commercial operations simultaneously. A platform that can’t adapt to that reality will eventually become a constraint, not an enabler. 

Built for this, not adapted to it 

One of the core reasons OCELLOS can move at the speed it does is that it was designed specifically for cell and gene therapy from the ground up, not adapted from a broader enterprise platform. 

That distinction matters more than it might sound. When a platform has been repurposed from a different domain, CGT-specific requirements become customizations. And customizations mean implementation time, project risk, and long-term maintenance complexity. When a platform is purpose-built, those requirements are simply features. 

OCELLOS is also modular. Therapy developers can deploy exactly what they need at each stage of their program, without having to implement the entire platform to get started. That changes the economics and the risk profile of adoption in a meaningful way. 

In practical terms, this means a customer can be live for a clinical study in as little as three weeks. Moving through to commercial launch, even where integrations, external partners, and regulatory requirements are all in play, is achievable in months, not a year or more. Typically around six months in scenarios of that complexity. 

Start small, scale without starting over 

Perhaps the most important shift in how we think about deployment is the idea that early value shouldn’t require waiting for full implementation. 

Traditional approaches ask you to commit to the end state before seeing any return. The full platform, the complete integration landscape, the end-to-end program, all of it needs to be in place before operations can begin. That model made sense in a different era of enterprise software. It doesn’t fit the pace or risk profile of CGT development. 

Our approach is different. Therapy developers can start small and safely, with a deployment scope that matches where they actually are in their program. They can begin learning from real operational data early, which shapes better decisions about how they scale. And when they do scale, they don’t need to re-platform or re-implement. The foundation they start with is the same one they grow on. 

This matters because the cost of getting it wrong compounds. A platform that requires replacement at scale isn’t just an IT problem; it’s an operational disruption at exactly the moment when commercial execution is the priority. 

Rethinking what “proven” looks like 

There’s a version of digital transformation in this industry that prioritizes architectural ambition, large-scale programs with impressive scope and comprehensive design. We’re not suggesting there’s no value in thinking big. 

But from a commercial standpoint, the question that matters most is how quickly a platform can support a therapy reaching the patients who need it. Implementation timelines aren’t just an IT consideration; they are a commercial variable. Getting a platform to the point where sites can be trained and onboarded is critical, as it directly impacts the pace and feasibility of the site roll-out plan. 

A platform’s track record in live operations matters as much as its technical roadmap. OCELLOS is proven across clinical and commercial therapies, in real-world conditions with the kind of partner and regulatory complexity that commercial launches actually involve. 

That operational credibility, combined with the speed of deployment and the flexibility of a modular architecture, is what allows commercial teams to plan with confidence rather than build contingency into everything. You can commit to a launch timeline knowing the platform will be ready. You can scale into new markets or new therapies without the disruption of a re-implementation. And you can focus your energy on commercial execution rather than managing a transformation program running in parallel. 

If speed to commercial readiness, adaptability, and deep CGT-specific expertise are priorities for your program, we’d welcome the conversation.